Document is current
Any future updates will be listed below
-
Authors
Hamoy-Jimenez, G.
Elahmar, H. A.
Mendoza, M.
Kim, R. H.
Bril, V.
Barnett, C. http://orcid.org/0000-0001-5546-0221
- License Information
-
More Information
Article History
Received: 15 October 2021
Accepted: 30 January 2022
First Online: 8 February 2022
Declarations
:
: This study was approved by the University Health Network research ethics board and all participants provided written informed consent.
: Not applicable.
: GHJ declares no competing interests. HAE declares no competing interests. MM declares no competing interests. RK declares no competing interests. VB has been a consultant to Grifols, CSL Behring, UCB, Argenx, Takeda (Shire), Alnylam, Octapharma, Powell Mansfield Inc., Akcea, Immunovant and Alexion; she has received research support from Grifols, CSL Behring, UCB, Argenx, Takeda (Shire), Octapharma, Baxalta and Biogen. CB declares research grant form US Department of Defense, MGNet and Muscular Dystrophy Canada, Grifols and Octapharma. She has been consultant for Alexion, Sanofi, Argenx, Takeda and CSL. No disclosures are related to this study.
